Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Ocoee, Florida Clinical Trials

A listing of Ocoee, Florida clinical trials actively recruiting patient volunteers.

RESULTS

Found (30) clinical trials

Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis

The purpose of the study is to determine the efficacy, dose response, and safety of evobrutinib in subjects with Rheumatoid Arthritis (RA), and to consider a dose to take forward into Phase III development.

Phase

8.38 miles

Learn More »

An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)

This is a study comparing the defibrotide prophylaxis arm vs standard of care arm for the prevention of aGvHD.

Phase

8.38 miles

Learn More »

A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib.

Phase

9.82 miles

Learn More »

Study of IFN-K in Systemic Lupus Erythematosus

The safety and immunogenicity of the IFN-Kinoid (IFN-K) have been evaluated in a phase I clinical study conducted in subjects with SLE. Preliminary results were promising. The principal aim of the present study is to confirm the neutralization of the interferon gene signature and the clinical efficacy of IFN-K in ...

Phase

9.82 miles

Learn More »

Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis

The purpose of this study is to evaluate the safety and efficacy of oral omadacycline as compared to oral nitrofurantoin in the treatment of female adults with cystitis.

Phase

9.82 miles

Learn More »

A Study to Evaluate the Efficacy Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis

This is a multicenter, randomized, parallel-group, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of SEP-363856 flexibly dosed at 25, 50, or 75 mg/day for 6 weeks in male and female subjects 55 years of age with a clinical diagnosis of PDP. The study will randomize approximately 36 subjects ...

Phase

9.82 miles

Learn More »

Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy

This is a multicenter, open-label study comprised of pretreatment, treatment (core study), and extension phases that is designed to evaluate the PK of an oral suspension of perampanel (target dose of 12 milligrams per day [mg /day] for non-enzyme-inducing antiepileptic drug [non-EIAED] or 16 mg/day for EIAED) when given as ...

Phase

9.9 miles

Learn More »

A Phase 2 Prospective Interventional Open-Label Multi-Site Extension Study to Assess the Long-Term Safety and Tolerability of TAK-935 (OV935) as Adjunctive Therapy in Patients With Rare Epilepsy

The drug being tested in this study is called TAK-935 (OV935). This global, open-label study will assess the safety and tolerability of TAK-935 for 2 years in patients who participated in previous short-term efficacy/safety studies of TAK-935. All patients will receive TAK-935 treatment. Patients who rollover from previous blinded study ...

Phase

9.9 miles

Learn More »

A Phase 2 Multicenter Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy Safety and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Patients With Developmental and/or Epileptic Encephalopathies

The drug being tested in this study is called TAK-935 (OV935). This randomized, double-blind study will assess the effects of TAK-935 (OV935), compared to placebo, on efficacy, safety, and tolerability in pediatric patients with Dravet syndrome or LGS. This multi-center trial will be conducted worldwide and will enroll approximately 126 ...

Phase

9.9 miles

Learn More »

A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis.

This is a phase 2 study to evaluate safety and efficacy of ABBV-105 and ABBV-599 (ABBV-105 plus upadacitinib) vs placebo on a background of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDS) for the treatment of signs and symptoms of Rheumatoid Arthritis (RA) at 12 weeks in biological disease-modifying anti-rheumatic drugs(bDMARD)-inadequate response ...

Phase

9.9 miles

Learn More »